Interleukin-21 induces proliferation and modulates receptor expression and effector function in canine natural killer cells

Veterinary Immunology and Immunopathology

Volumn 165, Issue 1-2, 2015, Pages 22-33

  Shin, Dong Jun ^a   Lee, Soo Hyeon ^a,b   Park, Ji Yun ^a   Kim, Ju Sun ^a,b   Lee, Je Jung ^b   Suh, Guk Hyun ^d   Lee, Youn Kyung ^b   Cho, Duck ^b,c   Kim, Sang Ki ^a  

^a Kongju National University   (South Korea)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

Canine; Effector function; Interleukin 21; NK cells; Proliferation

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; MESSENGER RNA; PERFORIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA BETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA DELTA CHAIN; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG; EFFECTOR CELL; EX VIVO STUDY; GAMMA IRRADIATION; GENE EXPRESSION; K562 CELL LINE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD5; CELL PROLIFERATION; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKINS; KILLER CELLS, NATURAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, COMPLEMENT 3D;

EID: 84928763151     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2015.03.004     Document Type: Article

References (30)

1. Berg M., Lundqvist A., McCoy P., Samsel L., Fan Y., Tawab A., Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355.
2. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 2004, 172:2048-2058.
3. Brady J., Carotta S., Thong R.P., Chan C.J., Hayakawa Y., Smyth M.J., Nutt S.L. The interactions of multiple cytokines control NK cell maturation. J. Immunol. 2010, 185:6679-6688.
4. Burgess S.J., Marusina A.I., Pathmanathan I., Borrego F., Coligan J.E. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J. Immunol. 2006, 176:1490-1497.
5. Chouaib S., Pittari G., Nanbakhsh A., El Ayoubi H., Amsellem S., Bourhis J.H., Spanholtz J. Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front. Immunol. 2014, 5:95.
6. de Rham C., Ferrari-Lacraz S., Jendly S., Schneiter G., Dayer J.M., Villard J. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthr. Res. Ther. 2007, 9:R125.
7. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., Singh H., Hurton L., Maiti S.N., Huls M.H., Champlin R.E., Cooper L.J., Lee D.A. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PloS One 2012, 7:e30264.
8. Huang Y.C., Hung S.W., Jan T.R., Liao K.W., Cheng C.H., Wang Y.S., Chu R.M. CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J. Leuko. Biol. 2008, 84:1501-1510.
9. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376-383.
10. Kasaian M.T., Whitters M.J., Carter L.L., Lowe L.D., Jussif J.M., Deng B., Johnson K.A., Witek J.S., Senices M., Konz R.F., Wurster A.L., Donaldson D.D., Collins M., Young D.A., Grusby M.J. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569.
11. Knapp D.W., Leibnitz R.R., DeNicola D.B., Turek J.J., Teclaw R., Shaffer L., Chan T.C. Measurement of NK activity in effector cells purified from canine peripheral lymphocytes. Vet. Immunol. Immunopathol. 1993, 35:239-251.
12. Lim D.P., Jang Y.Y., Kim S., Koh S.S., Lee J.J., Kim J.S., Thi Phan M.T., Shin D.J., Shin M.G., Lee S.H., Yoon M., Kim S.K., Yoon J.H., Park M.H., Cho D. Effect of exposure to interleukin-21 at various time points on human natural killer cell culture. Cytotherapy 2014, 10.1016/j.jcyt.2014.04.008.
13. Lin Y.C., Huang Y.C., Wang Y.S., Juang R.H., Liao K.W., Chu R.M. Canine CD8T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Vet. Immunol. Immunopathol. 2010, 133:144-153.
14. Loughran T.P., Deeg H.J., Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell. Immunol. 1985, 95:207-217.
15. Marcais A., Viel S., Grau M., Henry T., Marvel J., Walzer T. Regulation of mouse NK cell development and function by cytokines. Front. Immunol. 2013, 4:450.
16. Meazza R., Azzarone B., Orengo A.M., Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J. Biomed. Biotechnol. 2011, 2011:861920.
17. Michael H.T., Ito D., McCullar V., Zhang B., Miller J.S., Modiano J.F. Isolation and characterization of canine natural killer cells. Vet. Immunol. Immunopathol. 2013, 155:211-217.
18. Miller J.S., Rooney C.M., Curtsinger J., McElmurry R., McCullar V., Verneris M.R., Lapteva N., McKenna D., Wagner J.E., Blazar B.R., Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol. Blood Marrow Transplant. 2014, 20:1252-1257.
19. Moretta L., Pietra G., Montaldo E., Vacca P., Pende D., Falco M., Del Zotto G., Locatelli F., Moretta A., Mingari M.C. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front. Immunol. 2014, 5:87.
20. Nakada Y., Tokumitu K., Kosaka T., Kuwabara M., Tanaka S., Koide F. Correlation between canine NK cell mediated cytotoxicity and radical production. Vet. Immunol. Immunopathol. 1995, 45:285-295.
21. Park Y.K., Shin D.J., Cho D., Kim S.K., Lee J.J., Shin M.G., Ryang D.W., Lee J.S., Park M.H., Yoon J.H., Jegal Y.J. Interleukin-21 increases direct cytotoxicity and IFN-gamma production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res. 2012, 32:839-846.
22. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J.L., Kramer J., Conklin D., Presnell S.R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F.J., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R.D., Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
23. Parrish-Novak J., Foster D.C., Holly R.D., Clegg C.H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J. Leukoc. Biol. 2002, 72:856-863.
24. Ringler S.S., Krakowka S. Cell surface markers of the canine natural killer (NK) cell. Vet. Immunol. Immunopathol. 1985, 9:1-11.
25. Shin D.J., Park J.Y., Jang Y.Y., Lee J.J., Lee Y.K., Shin M.G., Jung J.Y., Carson W.E., Cho D., Kim S.K. Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. Vet. Immunol. Immunopathol. 2013, 153:249-259.
26. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008, 123:575-583.
27. Strengell M., Matikainen S., Siren J., Lehtonen A., Foster D., Julkunen I., Sareneva T. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J. Immunol. 2003, 170:5464-5469.
28. Sutlu T., Stellan B., Gilljam M., Quezada H.C., Nahi H., Gahrton G., Alici E. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010, 12:1044-1055.
29. Toomey J.A., Gays F., Foster D., Brooks C.G. Cytokine requirements for the growth and development of mouse NK cells in vitro. J. Leukoc. Biol. 2003, 74:233-242.
30. Varchetta S., Oliviero B., Mavilio D., Mondelli M.U. Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity. Cytokine 2013, 62:58-63.